Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells

Zeng,Yan‑Ping; Yang,Chao; Li,Yuan; Fan,Yong; Yang,Hong‑Jun; Liu,Bin; Sang,Hong‑Xun

doi:10.3892/mmr.2016.5456

Aspirin inhibits osteoclastogenesis by suppressing the activation of NF-κB and MAPKs in RANKL-induced RAW264.7 cells

Authors:
- Yan‑Ping Zeng
- Chao Yang
- Yuan Li
- Yong Fan
- Hong‑Jun Yang
- Bin Liu
- Hong‑Xun Sang
View Affiliations

Affiliations: Department of Orthopedic Surgery, Institute of Orthopedics, Xijing Hospital, The Fourth Military Medical University, Xi'an, Shaanxi 830054, P.R. China
Published online on: June 30, 2016 https://doi.org/10.3892/mmr.2016.5456
Pages: 1957-1962
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Aspirin is a commonly used medicine as an effective antipyretic, analgesic and anti-inflammatory drug. Previous studies have demonstrated its potential effects of anti-postmenopausal osteoporosis, while the molecular mechanisms remain unclear. The effects of aspirin on receptor‑activator of nuclear factor κB (NF‑κB) ligand (RANKL)‑induced osteoclasts were investigated in RAW264.7 cells in the current study. Using tartrate‑resistant acid phosphatase (TRAP) staining, it was observed that aspirin inhibited the differentiation of RANKL‑induced RAW264.7 cells. The mRNA expression of osteoclastic marker genes, including cathepsin K, TRAP, matrix metalloproteinase 9 and calcitonin receptor, were suppressed by aspirin as identified using reverse transcription‑quantitative polymerase chain reaction analysis. The immunofluorescence assay indicated that aspirin markedly inhibited NF‑κB p65 translocation to the nucleus in RANKL‑induced RAW264.7 cells. In addition, aspirin also suppressed the phosphorylation of mitogen‑activated protein kinases (MAPKs), observed by western blot analysis. Taken together, these data identified that aspirin inhibits osteoclastogenesis by suppressing the activation of NF‑κB and MAPKs in RANKL‑induced RAW264.7 cells, implying that aspirin may possess therapeutic potential for use in the prevention and treatment of osteoporosis.

View Figures

View References

1	Boyle WJ, Simonet WS and Lacey DL: Osteoclast differentiation and activation. Nature. 423:337–342. 2003. View Article : Google Scholar : PubMed/NCBI
2	Armstrong AP, Tometsko ME, Glaccum M, Sutherland CL, Cosman D and Dougall WC: A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function. J Biol Chem. 277:44347–44356. 2002. View Article : Google Scholar : PubMed/NCBI
3	Wei S, Teitelbaum SL, Wang MW and Ross FP: Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology. 142:1290–1295. 2001.PubMed/NCBI
4	Matsumoto M, Sudo T, Saito T, Osada H and Tsujimoto M: Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-kappa B ligand (RANKL). J Biol Chem. 275:31155–31161. 2000. View Article : Google Scholar : PubMed/NCBI
5	David JP, Sabapathy K, Hoffmann O, Idarraga MH and Wagner EF: JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms. J Cell Sci. 115:4317–4325. 2002. View Article : Google Scholar : PubMed/NCBI
6	Lee SE, Woo KM, Kim SY, Kim HM, Kwack K, Lee ZH and Kim HH: The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved inosteoclast differentiation. Bone. 30:71–77. 2002. View Article : Google Scholar : PubMed/NCBI
7	Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, et al: Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 428:758–763. 2004. View Article : Google Scholar : PubMed/NCBI
8	Baltas CS, Balanika AP, Raptou PD, Tournis S and Lyritis GP; Hellenic guidelines on bone densitometry working group: Clinical practice guidelines proposed by the Hellenic Foundation of Osteoporosis for the management of osteoporosis based on DXA results. J Musculoskelet Neuronal Interact. 5:388–392. 2005.PubMed/NCBI
9	Valverde P: Pharmacotherapies to manage bone loss-associated diseases: A quest for the perfect benefit-to-risk ratio. Curr Med Chem. 15:284–304. 2008. View Article : Google Scholar : PubMed/NCBI
10	Li L and Seeram NP: Further investigation into maple syrup yields 3 new lignans, a new phenylpropanoid, and 26 other phytochemicals. J Agric Food Chem. 59:7708–7716. 2011. View Article : Google Scholar : PubMed/NCBI
11	Bauer DC, Orwoll ES, Fox KM, Vogt TM, Lane NE, Hochberg MC, Stone K and Nevitt MC: Aspirin and NSAID use in older women: Effect on bone mineral density and fracture risk. Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 11:29–35. 1996. View Article : Google Scholar : PubMed/NCBI
12	Chen ZW, Wu ZX, Sang HX, Qin GL, Wang LS, Feng J, Wang J, Li XJ, Wang JC and Zhang D: Effect of aspirin administration for the treatment of osteoporosis in ovariectomized rat model. Zhonghua Yi Xue Za Zhi. 91:925–929. 2011.In Chinese. PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
14	Raisz LG: Pathogenesis of osteoporosis: Concepts, conflicts, and prospects. J Clin Invest. 115:3318–3325. 2005. View Article : Google Scholar : PubMed/NCBI
15	Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA and Wagner EF: c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science. 266:443–448. 1994. View Article : Google Scholar : PubMed/NCBI
16	Mansky KC, Sankar U, Han J and Ostrowski MC: Microphthalmia transcription factor is a target of the p38 MAPK pathway in response to receptor activator of NF-kappa B ligand signaling. J Biol Chem. 277:11077–11083. 2002. View Article : Google Scholar : PubMed/NCBI
17	Gingery A, Bradley E, Shaw A and Oursler MJ: Phosphatidylinositol 3-kinase coordinately activates the MEK/ERK and AKT/NFkappaB pathways to maintain osteoclast survival. J Cell Biochem. 89:165–179. 2003. View Article : Google Scholar : PubMed/NCBI
18	Mohamed SG, Sugiyama E, Shinoda K, Taki H, Hounoki H, Abdel-Aziz HO, Maruyama M, Kobayashi M, Ogawa H and Miyahara T: Interleukin-10 inhibits RANKL-mediated expression of NFATc1 in part via suppression of c-Fos and c-Jun in RAW264.7 cells and mouse bone marrow cells. Bone. 41:592–602. 2007. View Article : Google Scholar : PubMed/NCBI
19	Anusaksathien O, Laplace C, Li X, Ren Y, Peng L, Goldring SR and Galson DL: Tissue-specific and ubiquitous promoters direct the expression of alternatively spliced transcripts from the calcitonin receptor gene. J Biol Chem. 276:22663–22674. 2001. View Article : Google Scholar : PubMed/NCBI
20	Motyckova G, Weilbaecher KN, Horstmann M, Rieman DJ, Fisher DZ and Fisher DE: Linking osteopetrosis and pycnodysostosis: Regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc Natl Acad Sci USA. 98:5798–5803. 2001. View Article : Google Scholar : PubMed/NCBI
21	Reddy SV, Hundley JE, Windle JJ, Alcantara O, Linn R, Leach RJ, Boldt DH and Roodman GD: Characterization of the mouse tartrate-resistant acid phosphatase (TRAP) gene promoter. J Bone Miner Res. 10:601–606. 1995. View Article : Google Scholar : PubMed/NCBI
22	Choi HJ, Park YR, Nepal M, Choi BY, Cho NP, Choi SH, Heo SR, Kim HS, Yang MS and Soh Y: Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways. Eur J Pharmacol. 636:28–35. 2010. View Article : Google Scholar : PubMed/NCBI
23	Bharti AC, Takada Y and Aggarwal BB: Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol. 172:5940–5947. 2004. View Article : Google Scholar : PubMed/NCBI
24	Ghosh S and Karin M: Missing pieces in the NF-kappaB puzzle. Cell. 109(Suppl): S81–S96. 2002. View Article : Google Scholar : PubMed/NCBI
25	Karin M, Yamamoto Y and Wang QM: The IKK NF-kappa B system: A treasure trove for drug development. Nat Rev Drug Discov. 3:17–26. 2004. View Article : Google Scholar : PubMed/NCBI